Cyclerion Therapeutics, Inc. (CYCN)
| Market Cap | 18.38M +125.5% |
| Revenue (ttm) | 1.90M -12.6% |
| Net Income | -6.71M |
| EPS | -1.73 |
| Shares Out | 4.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,085 |
| Open | 4.100 |
| Previous Close | 4.150 |
| Day's Range | 3.940 - 4.260 |
| 52-Week Range | 1.027 - 8.480 |
| Beta | 1.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About CYCN
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufa... [Read more]
Financial Performance
In 2025, Cyclerion Therapeutics's revenue was $2.07 million, an increase of 3.70% compared to the previous year's $2.00 million. Losses were -$3.53 million, 15.4% more than in 2024.
Financial StatementsNews
Why is Cyclerion Therapeutics Stock (CYCN) Up Over 160% Today?
Shares in biopharmaceutical group Cyclerion Therapeutics ($CYCN) powered 165% higher in pre-market trading today after it said it was merging with peer Korsana Biosciences to help find a treatment for...
Cyclerion Therapeutics, Korsana Biosciences enter merger agreement
Cyclerion Therapeutics (CYCN) and Korsana Biosciences entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
WALTHAM, Mass.--(BUSINESS WIRE)---- $CYCN--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...
Cyclerion receives positive written feedback, responses on CYC-126 study
Cyclerion Therapeutics (CYCN) announced it has received positive written regulatory feedback and responses from the FDA on CYC-126’s Phase 2 POC study in TRD and its path to potential regulatory…
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatr...
Cyclerion Therapeutics enters exclusive collaboration with Medsteer
Cyclerion Therapeutics (CYCN) announced an application-specific, exclusive collaboration with Medsteer. The new collaboration agreement expands upon the parties’ existing development collaboration and...
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of...
Cyclerion enters licensing agreement with MIT, announces strategic relaunch
Cyclerion Therapeutics (CYCN) announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology, securing the intellectual property that will serve as the corners...
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
Cyclerion Therapeutics files to sell 500K shares of common stock for holders
The company is not selling any shares of its common stock, and will not receive any of the proceeds from the sale of shares by the selling stockholders. Published first…
Cyclerion Therapeutics files $25M mixed securities shelf
16:43 EST Cyclerion Therapeutics (CYCN) files $25M mixed securities shelf
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Cyclerion Therapeutics (CYCN), 2,700% surge in interest N...
Cyclerion Therapeutics announces update on next stage of growth
Cyclerion Therapeutics (CYCN) announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase, sGC, stimulator asse...
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Cyclerion Therapeutics (CYCN), 1,754% surge in interest T...
Cyclerion Therapeutics appoints Regina Graul as CEO
Cyclerion Therapeutics announced that Regina Graul, Ph.D., has been promoted to CEO, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December…
Regina Graul, Ph.D., Promoted to Chief Executive Officer
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.
Cyclerion Therapeutics appoints Graul as President
Cyclerion Therapeutics announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion’s president, she will lead the organization and will work closely wi...
Cyclerion Appoints Regina Graul, Ph.D., as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurologic...
Cyclerion Therapeutics, Tisento close asset purchase agreement
Cyclerion Therapeutics and Tisento Therapeutics announced the closing of the previously disclosed asset purchase agreement. Tisento is launching with an $81M Series A financing to support its developm...
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stoc...
Cyclerion Announces Reverse Stock Split
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stoc...
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction